Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nicox S.A. (ALCOX.PA)
Valbonne, FR
Nicox S.A. is an ophthalmology firm operating both within France and internationally, dedicated to developing treatments that preserve sight and enhance eye health. Its most advanced investigational therapy, NCX 470, is a unique nitric oxide-donating bimatoprost eye drop currently undergoing Phase 3 clinical trials, designed to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company is also progressing NCX 4251, a proprietary ophthalmic suspension containing fluticasone propionate nanocrystals, which is in Phase 2b development for the treatment of dry eye disease. Additionally, Nicox has NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, in its preclinical assessment stage. Beyond its pipeline, Nicox markets VYZULTA, a latanoprostene bunod ophthalmic solution prescribed for open-angle glaucoma or ocular hypertension, and ZERVIATE, a cetirizine ophthalmic solution used to alleviate ocular itching linked to allergic conjunctivitis. Established in 1996, Nicox S.A. maintains its headquarters in Valbonne, France.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.53% | -1.05% | -6.92% | -2.71% | +13.40% | +26.34% | +70.98% | -37.15% | -91.06% | -95.83% | -99.66% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+113.4% ★ Q4'25: -100.0% (vs Q2'22)
-
EPS growth Biotechnology: +29.7%+93.9% ★ Q4'25: +114.8% (vs Q2'22)
-
FCF margin FCF growth · Biotechnology: +16.2%+95.2%
-
EBIT margin Biotechnology: +0.0%+3.2% ★
-
ROIC Biotechnology: -16.1%+23.6% ★
-
Share dilution Biotechnology: -3.4%+76.8% Q4'25: -100.0% (vs Q2'22)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.02× ★
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
6.90M
est: 5.24M (+31.7%)
|
7.86M
est: 4.90M (+60.4%)
|
16.77M
est: 16.20M (+3.5%)
|
3.00M
3.00M – 3.00M
-81.5% YoY
|
10.00M
10.00M – 10.00M
+233.3% YoY
|
| EBITDA |
-19.70M
est: -5.24M (-276.0%)
|
-20.56M
est: -2.94M (-599.2%)
|
18.91M
est: -9.72M (+294.5%)
|
-1.80M
-1.80M – -1.80M
+81.5% YoY
|
-6.00M
-6.00M – -6.00M
-233.3% YoY
|
| EBIT |
-19.73M
est: -5.24M (-276.4%)
|
-20.57M
est: -3.89M (-429.1%)
|
537.6K
est: -12.86M (+104.2%)
|
-2.38M
-2.38M – -2.38M
+81.5% YoY
|
-7.94M
-7.94M – -7.94M
-233.3% YoY
|
| Net Income |
-20.88M
est: -14.97M (-39.5%)
|
-22.39M
est: -22.03M (-1.6%)
|
-2.41M
est: -881.3K (-173.8%)
|
-6.17M
-6.17M – -6.17M
-600.0% YoY
|
881.3K
881.3K – 881.3K
+114.3% YoY
|
| SGA |
2.94M
est: 4.58M (-35.9%)
|
4.23M
est: 3.83M (+10.4%)
|
—
est: 12.66M (-100.0%)
|
2.34M
2.34M – 2.34M
-81.5% YoY
|
7.81M
7.81M – 7.81M
+233.3% YoY
|
| EPS |
-0.42
est: -0.30 (-40.0%)
|
-0.35
est: -0.25 (-40.0%)
|
-0.03
est: -0.01 (-174.0%)
|
-0.07
-0.07 – -0.07
-600.0% YoY
|
0.01
0.01 – 0.01
+114.3% YoY
|
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Gavin Spencer | Chief Executive Officer & Director | 300.0K | — |
| Doug Hubatsch | Executive Vice President & Chief Scientific Officer | — | male |
| Jose Boyer | Consultant | — | — |
| Ramesh Krishnamoorthy | Senior Director and Head of Late Stage CMC & Quality Control | — | — |
| Sandrine Gestin | Vice President of Finance & Human Resources | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ALCOX.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
